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Resistance to erythromycin in pneumococci
has been observed since 1967 (1) and was first
reported in South African multiresistant pneu-
mococcal strains in 1978 (2). Until recently, the
only mechanism described for resistance to
erythromycin in the pneumococcus was the N6-
methylation of a specific adenine residue (A2058)
in 23S rRNA, which resulted in reduced affinity
between the antibiotic and the ribosome (3,4).
This resistance is associated with the gene
ermAM (5), first described in Streptococcus
sanguis (6). Since then, other mechanisms of
erythromycin resistance in the pneumococcus
have been reported. In fact, most resistance in the
United States appears to be due to efflux of the
antibiotic from the cell, associated with the gene
mefE (7,8). While ermAM confers coresistance to
most macrolides, lincosamides, and streptogramin
B antibiotics (resulting in the so-called MLS
phenotype) (3,9), mefE confers resistance only to
the 14- and 15-membered macrolides (resulting in
the M phenotype) (7,8). We report the emergence of
M-phenotype erythromycin resistance in South
African blood and cerebrospinal fluid (CSF)
pneumococcal isolates from 1987 to 1996.
The South African Institute for Medical
Research (SAIMR), Johannesburg, South Africa,
regularly receives all pneumococcal isolates from
participating laboratories in eight of the nine
provinces of South Africa. We examined all
erythromycin-resistant blood and CSF isolates
received by SAIMR from 1987 to 1996.
Erythromycin-, clindamycin-, and penicillin-
resistance phenotypes were determined by using
disk diffusion assays (erythromycin, 15µg/disk,
clindamycin, 2 µg/disk, oxacillin, 1 µg/disk) on 5%
horse blood agar plates (Mueller-Hinton base)
after overnight growth at 37oC under aerobic
conditions. Strains showing resistance (zone
diameters  £ 20mm for erythromycin, £ 18mm for
clindamycin, and <20mm for oxacillin) on the
disk diffusion plates were tested by the agar
dilution method to obtain MICs according to the
National Committee for Clinical Laboratory
Standards guidelines (10). We evaluated (by the
chi-square test) increases in the prevalence of
erythromycin resistance and the incidence of
resistance to erythromycin and susceptibility to
clindamycin, which represents the M phenotype.
The M phenotype increased significantly
from 1987 to 1991 compared with 1992 to 1996 in
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Erythromycin-resistant pneumococci have been isolated in South Africa since 1978;
however, from 1987 to 1996, resistance to macrolides was only detected in 270 (2.7%)
of 9,868 blood or cerebrospinal fluid (CSF) pneumococcal isolates, most of which were
obtained from the public sector. In South Africa, macrolide use in the public sector is
estimated at 56% of that in the private sector. Most erythromycin-resistant strains (89%)
exhibited resistance to erythromycin and clindamycin (macrolide-lincosamide-
streptogramin B phenotype). In the United States, most erythromycin-resistant
pneumococci exhibit the newly described M phenotype (resistance to erythromycin
alone), associated with the mefE gene. The M phenotype in South Africa increased
significantly in the last 10 years, from 1 of 5,115 to 28 of 4,735 of blood and CSF isolates
received from 1987 to 1991 compared with 1992 to 1996 (p = 5x10-7). These data
suggest that, although macrolide resistance in pneumococci remains low in the public
sector, the mefE gene is rapidly emerging in South Africa.278 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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blood and CSF isolates—from 1 of 5,115 isolates
to 28 of 4,753 isolates (p = 5x10-7, odds ratio
[OR] 30.13, 95% confidence interval [CI] 4.1-
221) (Table 1; Figure).
Data on oral macrolides in the public sector
(from the Division of Medical Schemes Supplies
and Pharmaceutical Services of the Department
of Health) show that 16.4 million defined daily
doses (ddd) of macrolides were purchased for the
estimated 30.3 million persons who obtain health
care from the public sector (0.54 ddd per capita).
Private sector use for the year ending December
1997 (Intercontinental Medical Statistics South
Africa, Pty, Ltd., unpub. data) show that 7.3 million
ddd of macrolide were purchased in an estimated
population of 7.57 million (0.96 ddd per capita).
All 78 MLS isolates hybridized with the
ermAM probe or produced a 616-bp-amplification
product during polymerase chain reaction (PCR)
amplification using the ermAM-specific primers.1
The 12 M isolates tested contained the mefE gene
as shown by a 348bp-amplification product when
amplified using primers specific for mefE. There
were no erythromycin-resistant isolates that
contained neither the ermAM nor the mefE gene.
Erythromycin-resistant strains were
serotyped by using the quellung reaction and
antisera from the Staten Seruminstitut,
Copenhagen, Denmark. Over the 10 years, the
five most common serotypes and groups among
the erythromycin-resistant isolates in decreasing
order of frequency were serotype 14, serogroups
6, 19, 23, and serotype 1 (Table 2). Serotype 1
erythromycin-resistant pneumococci appeared
only after 1992; serotype 14 was the most
common in MLS isolates; serogroup 23 was the
most common serogroup in M isolates (Table 2).
Serotypes 14 and serogroups 6, 23, and 19 are the
most common serotypes and groups isolated from
children with serious infections (13,14). Of the
157 isolates from patients whose age was supplied,
98 (62%) were obtained from children (£12 years).
There was a trend that was not significant toward
more macrolide resistance in children than adults
(OR 1.17 [95% CI 0.98-1.39]). This trend may have
been significant if age data had been supplied with
all the isolates received. The proportion of
Table 1. Prevalence of South African erythromycin-
resistant pneumococcal isolates, 1987–1996a
Total No. of E-R No. of M strains
Years isolatesb strains (%)c (% of E-R strains)
1987-1991 5,115 128 (2.5)   1 (0.8)
1992-1996 4,753 142 (3.0) 28 (19.7)
Total 9,868 270 (2.7) 29 (10.7)
aOf 9,868 blood and cerebrospinal fluid (CSF) isolates
received by the SAIMR from 1987 to 1996, 270 were fully
resistant to erythromycin. While the number of erythromy-
cin-resistant blood and CSF isolates received increased from
1987 to 1991 compared with 1992 to 1996 (2.5% to 3.0%), the
increase was not significant. There was no significant
relationship between erythromycin resistance and the M
phenotype within any given province throughout the 10
years.
bBlood and cerebrospinal fluid isolates.
cE-R= erythromycin-resistant.
Figure. Number of erythromycin-resistant blood and
cerebrospinal fluid isolates of pneumococci.
1DNA was extracted from pneumococcal isolates by using a lysis solution consisting of 0.1% sodium deoxycholate as described
in (11), except that we used plate rather than broth cultures.
Seventy-eight MLS strains were probed for the ermAM gene by using dot blots. The probe (supplied by P. Courvalin,
Pasteur Institute, Paris, France) (Escherichia coli JM83/pUC19 560bp Ssp1 intragenic fragment of ermB) was labeled with
digoxygenin by using random primed labeling (DIG DNA Labeling and Detection Kit; Boeringer, Mannheim, Germany).
Hybridization and detection were performed following manufacturer’s instructions (DIG DNA Labeling and Detection Kit;
Boeringer, Mannheim, Germany). PCR was also used to detect ermAM in 30 strains according to standard conditions, with an
annealing temperature of 58°C. We used the following primers: forward primer, 5’-CGAGTGAAAAAGTACTCAACC, reverse
primer, 5’-GGCGTGTTTCATTGCTTGATG).
Published primers for the mefE gene (5’-AGTATCATTAATCACTAGTGC, and 5’-TTCTTCTGGTACTAAAAGTGG) (12)
were used to detect mefE through PCR amplification in 13 M strains. Amplification was performed in a Perkin Elmer Cetus
DNA Thermal Cycler under standard reaction conditions, with an annealing temperature of 56oC.279 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
Dispatches
pediatric isolates did not change significantly
over the 10-year period (63% during 1987 to 1991
and 62% the 1992 to 1996 period).
Approximately half of all the macrolide-
resistant isolates were also either intermediate
or fully resistant to penicillin (60 of the 128
isolates from the 1987 to 1991 period, and 72 of
the 142 isolates from the 1992 to 1996 period).
There was a trend (not significant) toward
greater resistance to penicillin in MLS strains. Of
the 78 strains with MICs available, 38 (49%) were
fully resistant (MIC ³  2 µg/ml) to penicillin, while
the rest showed intermediate resistance (1 µg £
MIC £ 0.12 µg). Previous data have indicated that
penicillin-intermediate resistance is far more
common in South Africa than full resistance to
penicillin (15). In 1992, Friedland and Klugman
(15) reported that only 3 of 35 penicillin-resistant
strains showed high-level resistance.
Coresistance to penicillin limits the use of most
macrolides as treatment of penicillin-resistant
pneumococcal infections. New semisynthetic
macrolides such as the ketolide RU 64004 (16) are
being developed, however, that do not show cross-
resistance to penicillin or to erythromycin.
Compared with total erythromycin resis-
tance (middle ear fluid, blood, and CSF) in
Europe (17-19), the United Kingdom (18), and the
United States (19,21,22), the overall prevalence
of macrolide resistance is low. In Europe
erythromycin resistance varies by country. In
Slovakia, almost all pneumococcal isolates are
resistant (17), whereas in Portugal only 0.6% of
isolates are resistant and the proportion appears
to be declining (23). In the United Kingdom,
erythromycin resistance increased from 3.3% to
8.6% between 1989 and 1992 in England and
Wales (20). In the United States, 10% of
pneumococcal isolates appear to be erythromycin
resistant (21). Most isolates received by SAIMR
are from the public sector, where macrolides are
not normally prescribed for pneumococcal
infections. Only 4 of the 128 erythromycin-
resistant isolates from 1987 to 1991 and 14 of the
142 erythromycin-resistant isolates from 1992 to
1996 were from the private sector. Resistance
data from the private sector may show much
higher levels of macrolide resistance, a conten-
tion supported by previous South African
resistance data (1986), where the carriage rates
of multiresistant pneumococci were 17.7% in
children from more affluent communities and 0%
in children from less affluent areas (24). MIC
data were available for 15 of the 20 multiresistant
isolates, and all 15 were fully resistant to both
erythromycin and clindamycin (24).
Before the M phenotype was observed,
erythromycin resistance was assumed to indicate
cross-resistance to lincosamides and
streptogramin B antibiotics in the pneumococcus.
The increase in the incidence of M phenotype may
warrant investigation into the use of these
antibiotics for the treatment of pneumococcal
infections. Sutcliffe et al. (7) suggested that
clindamycin be considered for the treatment of
bacteremia and middle ear and sinus infections
caused by Streptococcus pneumoniae. Treatment
with clindamycin is feasible only if infection with
gram-negative pathogens has been excluded and
if the S. pneumoniae phenotype is known because
the strain may show MLS resistance and studies
indicate that many penicillin-resistant strains
are also clindamycin-resistant (16,25). Visalli
and colleagues (25) found that clindamycin
concentrations of only 0.06 µg/ml were required
to inhibit 90% of penicillin-susceptible strains
when grown in air, while clindamycin concentra-
tions of >64 µg/ml were required to inhibit 90% of
penicillin-intermediate and -resistant strains.
Studies of streptogramin use against pneumo-
cocci show some promise. The streptogramin RP
59500, a mixture of type A streptogramin,
dalfopristin, and type B streptogramin quinupristin,
is active against pneumococci regardless of their
susceptibilities to penicillin or erythromycin
(26,27). In contrast to erythromycin, RP 59500 is
rapidly bactericidal (26). Clinical and bacteriologic
failure has, however, already been reported using
pristinamycin (28), an oral streptogramin combina-
tion from which RP 59500 was derived.
The M phenotype is thus relatively new in
South African pneumococci but is emerging as
an important factor in erythromycin-resistant
Table 2. Serotype distribution among erythromycin-
resistant pneumococci
Serotype/ No. (%) of No. (%) of Total no.
group MLSa isolates M isolates  (%) of isolates
14   96 (39.8)   9 (31.0) 105 (38.9)
  6   71 (29.5)   3 (10.3)   74 (27.4)
19   36 (14.9)   3 (10.3)   39 (14.4)
23   26 (10.8) 10 (34.5)   36 (13.3)
  1     7 (2.9)   1 (3.5)     8 (3.0)
Other     5 (2.1)   3 (10.3)     8 (3.0)
Total 241 29 270
aMLS, macrolides-lincosamides-streptogramin B.280 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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pneumococci. Although the low overall rate of
resistance makes the use of streptogramins and
lincosamides potentially more feasible for the
treatment of pneumococcal infections, coresistance
to penicillin and the present high rate of MLS
resistance necessitate antibiotic susceptibility
testing before these antibiotics are administered.
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